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Abstract
Background: Malignant glioma is a common primary tumor of the central nervous system. Brevican, an abundant
extracellular matrix component in the adult brain, plays a critical role in the process of glioma. The mechanisms for
the highly invasive behavior of gliomas are still poorly understood. The aim of this study was to examine whether
brevican is a predictor of glioma and its roles in glioma cell motility.
Methods: In this study, immunohistochemistry staining for brevican expression was performed in malignant
gliomas and benign controls. We also explored the effects of brevican on cell adhesion and migration in
brevican-overexpressed cells. Knockdown of brevican expression was achieved by stable transfection of U251 cells
transduced with a construct encoding a short hairpin DNA directed against the brevican gene, which
correspondingly, down-regulated the proliferation, invasion and spread of brevican-expressing cells. Moreover, the
role of brevican in the growth and progression of glioma was demonstrated by in vivo studies.
Results: Our results provide evidence for the molecular and cellular mechanisms that may underlie the
motility-promoting role of brevican in the progression of glioma. The role of brevican as a target for
immunotherapy might be taken into consideration in future studies.
Conclusions: This study suggests that expression of brevican is associated with glioma cell adhesion, motility and
tumor growth, and also is related to glioma cell differentiation, therefore it may be a marker for malignance degree
of glioma
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Background
Malignant glioma, the most common primary tumor in
the central nervous system (CNS) with an almost invari-
ably rapid and lethal outcome, is characterized by a dis-
tinctive ability to invade the surrounding tissue [1].
Tumor cell invasion is a particular problem at the time
of recurrence after the failure of anti-angiogenesis treat-
ment, resulting in neurological deficits and eventual pa-
tient demise [2,3]. Yet, at this time, no drug treatment is
available that can interfere with the invasiveness of ma-
lignant gliomas.
Brevican is one of the most abundant proteoglycans
(PGs) in the postnatal brain and is the smallest core
protein among the lectican family [4-6]; its gene is
located on chromosome 1q31 and includes 14 exons [7].
Recent studies have shown that brevican expression is
restricted within the CNS, including the brain and spinal
cord, but is absent in extracranial organs, such as the
heart, muscle, liver, kidney, lung, thymus and spleen [8].
Interesting, malignant gliomas exhibit unique brevican
isoforms, and brevican is critical for its proinvasive role
in glioma [9].
Brevican expression is induced in intracranial grafts of
invasive glioma cell lines [10]. Evidence has shown that
the coding sequence of the brevican gene in glioma is
the same as the brevican gene found in the cortex of the
normal brain. Therefore, the regulation of expression of
brevican in glioma is not caused by mutation [7]. To
date, our understanding of the regulatory mechanisms of
brevican functions and the involvement of PGs in cancer
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in the cerebrospinal fluid (CSF), we found brevican was
overexpressed in glioma patients. In this paper, the im-
plication of brevican in cancer development and pro-
gression is discussed. Our results demonstrated a
motogenic role for brevican and suggested that brevican
was a key enhancing factor in the progression of glioma.
Targeting brevican might offer a novel and promising
approach to cancer immunotherapy by engaging the
tumor microenvironment.
Methods
Tumor tissues of glioma and the control group
Formalin-fixed paraffin-embedded tissues from 60
patients with glioma of the astrocytoma cell types
(grades I, II, III and IV, n = 15 for each) and 40 patients
with non-glioma CNS tumors, including meningioma
(n = 20) and pituitary adenoma (n = 20), were used in
this study. All subjects (53 male, 47 female; aged 13–68
years) were retrieved from the archived cases at the De-
partment of Pathology, Fudan University, Shanghai Med-
ical School (Shanghai, China). The clinicopathological
characteristics of the 60 glioma patients are shown in
Table 1. All of these patients gave their informed con-
sent for this research. This study was approved by the
Institute Research Committee at Fudan University,
Shanghai Medical School.
Cell lines
The human glioma U251MG and U87 cell lines, and the
non-glioma cell line 293T were obtained from the
American Type Culture Collection (Manassas, VA). The
cells were grown in DMEM medium (Invitrogen, Grand
Island, NY) supplemented with 10% fetal bovine serum,
50 units/mL penicillin, and 50 μg/mL streptomycin in a
humidified atmosphere with 5% CO2 at 37°C.
Construction of recombinant plasmids and production of
anti-brevican antibodies
The pIRES-hrGFP-brevican plasmid containing the full
sequence of brevican was provided by a Department of
Neurology laboratory at the Beth Israel Deaconess Me-
dical Center. The brevican fragment was subcloned
into the pMX-puro(+) vector (Invitrogen) to yield
pMX-brevican, which was then transfected into 293T,
U251 and U87 cells using Fusion 6
W (Roche, Mann-
heim, Germany). In addition, the DNA sequence for
the N-terminal domain (aa 22–104) of brevican was ampli-
fied using the primers 5’-ACGGATCCGCAGATGTTCTG
GAAGGAGACA-3’ (P1) and 5’-CCGCTCGAGGTAGG
CCTCGTTCACCTTGAC- 3’ (P2). The brevican N-terminus
was also subcloned into the PGEX-4T-1 expression vector
(Invitrogen), and brevican recombinant protein was
obtained successfully. The anti-brevican antibody B5 was
obtained using immunized New Zealand rabbits, per-
formed as previously described [11].
Immunohistochemical (IHC) staining
The paraffin sections were dewaxed and hydrated, fol-
lowed by antigen repairing for 20 min. Rabbit anti-
brevican antibody (B5) was then added at 4°C overnight,
and horseradish peroxidase labeled anti-rabbit IgG at
37°C was incubated for 1 h. Then 0.05% DAB was added
for 5 min, hematoxylin for 1 min, and eosin for 2 min.
The IHC sections were stained by hematoxylin and eosin
(HE), and scanned under microscopy. The positive
index (PI) was calculated using the following formula-
tion: PI = i × p, where i is intensity of staining (0 for
negative, blue; 1 for weakly-positive, light yellow; 2 for
medium positive, yellow; 3 for strong positive, brown), and
p is positive percentage of staining (1 for ≤10%; 2 for
11%-50%; 3 for 51%-75%; 4 for >75%) [12]. The PI of glioma
specimens was compared with that of the control tumors.
Brevican knockdown
Knockdown of brevican expression was achieved using
recombinant plasmids containing short hairpin DNA
(shDNA), which were constructed by cloning the
respective shDNA into the pSuper-puro vector (Invitro-
gen). The candidate sequences of the shDNAs were as
follows: shDNA 1, 5’GATCCCCGGTGAACGAGGCCT
ACCGGTTCAAGAGACCGGTAGGCCTC GTTCACC
TTTTTGGAAA3’, shDNA 2, 5’GATCCCCGTTATGCT
GAAGACCTAAATTC AAGAGATTTAGGTCTTCAG
CATAACTTTTTGGAAA3’, shDNA 3, 5’GATCCCCG
GAG GAAGAAGAGAAATATTTCAAGAGAATATTT
CTCTTCTTCCTCCTTTTTGGAAA3’. A mock plasmid
Table 1 The characteristics of 60 patients with malignant
glioma
Characteristics Number of
patients
(N = 60; %)
Age (years)
≤50 32 (53.3)
>50 28 (46.7)
Gender
Male 30 (50.0)
Female 30 (50.0)
Histological grade
I 15 (25.0)
II 15 (25.0)
III 15 (25.0)
IV 15 (25.0)
Degree of differentiation
Well (hair cell type-, oligodendrocyte type- astrocytoma) 30 (50.0)
Poorly (anaplastic astrocytoma, glioblastoma) 30 (50.0)
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5’-GATCCCCGCTCCTAGAATTTGAAACATTCAAG
AGATGTTTCAAATTCTAGGAGCTTTTTGGAAA-3’.
Stably transduced U251 cells that overexpress brevican
were transfected with these plasmids for 24 h and then
treated with 1.0 μg/mL puromycin. The remaining cells
were cultured with 0.5 μg/mL puromycin until cell col-
onies formed, and Western blots were used to test for
brevican levels.
Cell adhesion and migration assays
The stably transduced cells were resuspended in culture
medium. A total of 50,000 suspended cells were added
to a 96-well plate coated with human fibronectin (20 μg/
mL; Solarbio, Beijing) and poly-L-lysine (50 μg/mL;
Sigma, St. Louis, MO). After an 1 h incubation, the
plates were washed with PBS, fixed with 4% paraformal-
dehyde, and the 570 nm absorbance was quantified after
crystal violet staining. For the migration assay, cells
A
B
**
*
Figure 1 Brevican expression levels were detected by immunohistochemistry staining using an anti-brevican antibody. (A) The staining
results were observed by microscopy. Meningioma was negative (a, blue;n= 20), pituitary adenoma was weakly-positive (b, light yellow;n= 20)
and malignant glioma sections (astrocytoma grades I-IV, n = 15 for each) were positive (c- f, yellow to brown; respectively). Hematoxylin was
used for nuclear counterstaining (blue). Left: 100×, HE staining (above), IHC (lower); right: 400×, magnification of square frame sections in the left;
(B) The immunohistochemistry PI of brevican expression in the gliomas (5.27 ± 1.98), especially for grade III and IV astrocytoma (6.07 ± 2.30
and 8.07± 2.22), was significantly higher than that of benign brain tumors (1.78 ± 0.89). *,P < 0.05; ** P < 0.01.
Lu et al. BMC Cancer 2012, 12:607 Page 3 of 10
http://www.biomedcentral.com/1471-2407/12/607diluted in serum-free culture medium were plated onto
24-well plates preloaded with Transwell inserts (8 μm
pore size; Costar, Cambridge, MA) at 50,000 cells per
well in 100 μl culture medium and allowed to migrate
for 10 h. Subsequently, the cells that had migrated to the
underside were stained and counted using microscopy.
All experiments were repeated at least three times.
Cell proliferation, invasion and wound healing assays
The transduced cells were plated on 24-well plates
(1000 cells/well) and the cell colonies were counted at
day 12 to measure the cell proliferation rate. For cell
invasion experiments, Matrigel was plated inside Trans-
well culture inserts for 5 h at 37°C before cells were
plated onto the inserts (50,000 cells/well). After 16 h,
the cells that migrated to the underside were stained
and counted.
For the cell wound healing assays, a cell scraper was
used to create scratch wound on a dish with cells grown
to 80% confluence. The distances of the wounds were
then measured using a microscope at 0, 24 and 48 h.
Cell motility was evaluated using the following formula:
cell motility = (distance24h or 48h – distance0h)/
distance0h.
Cytoimmunofluoresence staining
Cells were grown on a slide chamber for 24 h, fixed for
10 min in a cold mixture of methanol and acetone, and
blocked with PBST containing 0.5% bovine serum albu-
min for 2 h. Cells were incubated with anti-brevican
polyclonal antibody B5 (1: 100) overnight at 4°C, fol-
lowed by incubation with CF
™ 488A labeled goat anti-
rabbit secondary antibodies (Biotium, Hayward, CA) for
30 min at 37°C. The cells were then observed under
fluorescence microscopy.
Western blot
Whole cell lysates were used for immunoblotting as
described previously [13]. Enhanced chemiluminescence
detection was performed according to the manufac-
turer’s instructions with an ECL kit (Thermo Scientific,
Rockford, IL).
Tumorigenicity analysis
To validate the effects observed with brevican knock-
down in vitro, BALB/c nude mice were injected subcuta-
neously into the right flank with either the 5×10
6 U251
transduced cells, transduced U251/brevican-shDNA
mock, or transduced U251/ brevican-shDNA 2. BALB/c
nude mice (five mice per group) were purchased from
the National Rodent Laboratory Animal Resources
(Shanghai). Tumor measurements were made every
4 days and tumor sizes were calculated using the for-
mula V= 0.5a’ × b’
2, where a’ and b’ were the long and
short diameters of the tumor. In addition, 2×10
5 cells
were intracranially injected into the right thalamus of
BALB/c nude mice using a 10 μl syringe. A total volume
of 8 μl cell suspension was injected at 2.5 mm anterior
to the bregma and 2.0 mm lateral to the midline into
three mice for each group. Magnetic resonance tomog-
raphy (MRT) was used for comparing the orthotopic
tumor growth in the nude mice.
Statistical analysis
A one-way ANOVA was performed using SPSS 13.0
software (SPSS Inc., Chicago, IL). The results were
expressed as the means ± SD, and a P value < 0.05 was
considered to be statistically significant.
Results
Brevican is differentially expressed in glioma and benign
brain tumors
Immunohistochemical staining of 60 glioma tissue and
40 benign brain tumor samples showed that brevican
was located and overexpressed in the extracellular
matrix (ECM) and the cytoplasm of glioma cells,
whereas the meningioma and pituitary adenoma samples
were negative and weakly-positive, respectively. Diffuse
positive staining for brevican was observed in glioma
cells to varying degrees (Figure 1A c- f ), compared with
the benign tumor control group (Figure 1A a, b). The
staining was especially diffuse and infiltrative for grade
III and IV astrocytoma cells (Figure 1A e, f). The immu-
nohistochemistry PI of brevican expression in the
gliomas (5.27 ± 1.03) was significantly higher than that
of benign brain tumors (1.78 ± 0.86, P < 0.05).
Table 2 Brevican expression and the clinicopathological
characteristics of 60 patients with malignant glioma.
Cases Brevican expression Brevican expression P value
positive cases (%) negative cases (%)
Age
≤50 25 (78.1) 7 (21.9) 0.10
>50 16 (57.1) 12 (42.9)
Gender
Male 22 (73.3) 8 (26.7) 0.58
Female 19 (63.3) 11 (36.7)
Histological grade
I 6 (40.0) 9 (60.0) 0.01
II 9 (60.0) 6 (40.0)
III 12 (80.0) 3 (20.0)
IV 14 (93.3) 1 (6.7)
Degree of differentiation
Well 15 (50.0) 15 (50.0) 0.005
Poorly 26 (86.7) 4 (13.3)
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positive staining (PI > 4.0), whereas only 22.5% (9/40) of
the benign ones had positive staining, all of which were
heterogeneously positive (9/20) pituitary adenoma cells
(Figure 1B). In addition, the expression of brevican was
not correlated with the age or sex of the patients (with
P values of 0.10 and 0.58, respectively). However, the
expression of brevican in patients with well-differentiated
tumors was significantly higher than that of the patients
with poorly differentiated tumors (anaplastic astrocytoma
and glioblastoma) (P=0.005, Table 2).
Brevican overexpression promoted cell adhesion and
migration
The glioma U251 and U87 cell lines do not express bre-
vican in culture, probably due to the absence of micro-
environment of tumor growth, i.e. specific inducing
factors [8,14]. To overcome this limitation, we first gen-
erated pMX-mock- and pMX-brevican-stably- trans-
fected 293T cells, U251 cells and U87 cells. Western
blots revealed that pMX-brevican stably transduced
293T, U251 and U87 cells had much higher levels of
brevican expression than control cells (Figure 2A).
A
C
**
B 293T U251
Anti-Brevican
Anti-GAPDH
** **
U87
* **
Figure 2 Brevican overexpression promoted cell adhesion and migration. (A) Brevican expression levels of stably transduced pMX-brevican
cells were higher than those of control cells (B) Brevican expression enhanced fibronectin-dependent cell adhesion. PL, poly-L-lysine; FN,
fibronectin. (C) Stably transduced U251 and U87 cells demonstrated migration through transwell inserts. Cells were stained with HE (200×), and
the experiments were repeated at least three times; a: U251-MO; b: U251-BR; c: U87-MO; d: U87-BR; MO, the transduced cells with pMX-mock;
BR, the transduced cells with pMX-brevican. * P < 0.05; ** P < 0.01.
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cells, which were noted as “transduced U251 cells” were
used for brevican overexpression experiments. Cell
counting Kit-8 tests were used to ensure that the overex-
pression of brevican did not affect the proliferation of
the transduced 293T, transduced U251, and transduced
U87 cells (data not shown), as demonstrated previously
by Hu et al. [15]. In cell adhesion and migration assays,
the transduced cells generated traction and thereby
migrated through the substrate. In this study, the results
of the transwell assays showed that transfection with
pMX-brevican significantly promoted the migration of
U251 and U87 cells (Figure 2B). Moreover, brevican ex-
pression enhanced the fibronectin-dependent cell adhe-
sion (Figure 2C).
Knockdown of brevican gene inhibited cell motility
abilities
We knocked-down the brevican expression successfully
as revealed by Western blots (Figure 3A). Cell prolifera-
tion ability was significantly reduced in the transduced
U251/brevican-shDNA 2 cells compared with the trans-
duced U251 cells and the control cells by 85.8% and
83.6% at day 12 post plating, respectively (Figure 3B).
A B
C
Anti-Brevican
Anti-GAPDH
**
**
Figure 3 Brevican knockdown reduced glioma cell proliferation and invasion. (A) Brevican knockdown effectively down-regulated brevican
expression. Western blot analysis of cell lysates demonstrated down-regulation of brevican protein in the transduced U251/brevican-shDNA 2 and
the transduced U251/brevican-shDNA 3 cells by 52.3% and 23.4%, respectively. (B) Optical microscopic observation showed that cell colony
formation was inhibited in the transduced U251/brevican-shDNA 2 cells (c), compared with the transduced U251 cells (a) and the control cells (b).
(C) The rate of cell invasion was also reduced in the transduced U251/brevican-shDNA 2 cells (c) compared with the transduced U251 cells (a)
and control cells (b). TU, the transduced U251 cells (a); TU-shDNA mock, the transduced U251/brevican-shDNA mock cells (b); TU-shDNA2,
the transduced U251/brevican- shDNA 2 cells (c). ** P < 0.01.
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U251/brevican-shDNA 2 cells through the Matrigel were
dramatically decreased compared with the transduced
U251 cells and the control cells by 73.3% and 64.7%, re-
spectively (P < 0.01; Figure 3C). These results confirmed
that brevican plays an important role in glioma cell ad-
hesion and migration.
The influence of brevican on cell migration was fur-
ther observed in glioma cancer cells. The wound-healing
results indicated that the migration ability of the trans-
duced U251/brevican-shDNA 2 cells was also markedly
decreased (Figure 4A). As shown in Figure 4B, cytoim-
munofluoresence analyses showed cell infiltrating ability
was inhibited and brevican expression was decreased.
The spreading distance detected in the random
migration assays was significantly reduced in brevican
knockdown transfectants as compared with scrambled
control cells.
Brevican knockdown inhibits tumorigenicity in vivo
At the fourth week post-inoculation, the growth of
tumors formed by the transduced U251/brevican-
shDNA 2 cells was significantly suppressed (Figure 5A).
The xenograft transplants gave rise to much smaller
tumors than those from control cells (P < 0.05). In
addition, the brains of the nude mice injected intracrani-
ally were visualized with plain and Gd-DTPA-enhanced
MRT at day 25. Similar to transduced gliomas created
with another glioma cell line (CNS-1) [16,17], the trans-
duced U251/brevican-shDNA mock transfected cell-
A
** *
B Anti-Brevican B5 DAPI  Merge 
TU
TU-shDNA
mock
TU-shDNA 2
Figure 4 The motility of glioma cells was decreased by brevican knockdown. (A) A wound healing assay showed that the spreading ability
in the transduced U251/brevican-shDNA 2 cells was significantly inhibited by brevican knockdown at 24 and 48 h. (B) The live transduced cells
were incubated with anti-brevican antibody and subsequently processed for immunoassay. Cytoimmunofluorescence analyses also indicated
the cell infiltrating ability was inhibited and brevican expression was decreased in the transduced U251/brevican-shDNA 2 cells. Brevican
expression was reduced in the cytoplasm of glioma cells. TU, the transduced U251 cells; TU-shDNA mock, the transduced U251/brevican-mock
cells; TU-shDNA2, the transduced U251/ brevican-shDNA 2 cells. * P < 0.05; ** P < 0.01.
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that detached from the tumor core (Figure 5B a, c), as
well as extensive diffusion of single cells within the brain
parenchyma. However, transduced U251/brevican-
shDNA 2 cells produced smaller (Figure 5B b, d), less
diffuse and less infiltrative tumors than that of the con-
trol transduced U251/brevican-shDNA mock cell tumors
(volumes: 3.6 ± 1.5 mm
3 versus 10.3 ± 2.6 mm
3;n=3 ,
respectively; P < 0.01).
Discussion
The ECM has an active role in regulating the activity
and behavior of cells, including cell shape, differenti-
ation, proliferation and cell death. In recent studies, the
nervous ECM (NECM) was re-evaluated. To date, sev-
eral studies showed that the solubility of the NECM
increased in glioma, which might be related to the up-
regulation of brevican [18-21].
In this study, we first explored the physiological role
of brevican by investigating its spatiotemporal expres-
sion by IHC. Brevican was abundantly expressed in gli-
oma tissues, particularly in grade III and grade IV
astrocytomas, whereas brevican only expressed weakly
in pituitary adenoma tumor tissue and negative in men-
ingioma tissue. These data suggest that brevican is pro-
duced by astrocytoma cells, before being secreted and
bound to the cellular cytoplasm and ECM. In the trans-
duced brevican-expressing U251 cells, brevican was also
detected on the surface of these cells using cytoimmuno-
fluorescence. The expression of a tumor-specific
brevican found in all high-grade gliomas suggested that
it might play a significant role in glioma progression.
Moreover, previous studies have shown that brevican is
expressed at relatively low levels in normal adult brain
[10,22]. Therefore, the absence or down-regulation of
brevican in benign gliomas prompts its use as a differen-
tiation marker to distinguish primary brain tumors with
similar histology, but with a different pathologic course.
Here, we established an in vitro model to reproduce
the motogenic effects of brevican. Our results indicated
that brevican can promote cell adhesion and was essen-
tial for the migration of U251 cells. Brevican may inter-
act with fibronectin (FN) to act as a motogenic signal.
FN interacts with multiple cell surface receptors and
plays an important role in the regulation of anchorage-
dependent cell growth, cell migration, tumor develop-
ment and metastasis. Cell adhesion to immobilized FN
leads to the assembly of focal adhesions, which require
the small GTPase Rho and then affect many cellular
functions, such as cell motility, differentiation, matrix as-
sembly, and cell cycle progression [23]. A combination
of brevican cytological mechanisms and the particular
composition of the neural microenvironment may
underlie this unique ability of glioma to disperse in the
CNS. In addition, it has been demonstrated that secreted
brevican isoforms have evolved to become the predom-
inant brevicans in the adult brain [24]. Our studies sug-
gested that brevican overexpression in glioma is
associated with cancer progression, and therefore, brevi-
can might be a useful biomarker of glioma.
A B
a
b
c
d
**
**
**
1
2
3
Figure 5 The tumorigenicity of the transduced U251/brevican-shDNA 2 cells was reduced in nude mice. (A) Photograph of subcutaneous
tumors formed by the transduced U251 cells (1), the transduced U251/brevican-mock cells (2) and the transduced U251/ brevican-shDNA 2 cells
(3) groups (n=5) at day 28. Bars are 10 mm. (B) The plain MRT and Gd-DTPA-enhanced MRT results for brain sections showed that the
tumorigenicity of the transduced U251/brevican-shDNA 2 cells (b, d) was dramatically limited at day 25 (n=3), compared with the transduced
U251/brevican-shDNA mock cells (a, c). Also, the diffusion degree of the transduced U251/brevican-mock cells (a, c) was more extensive than the
transduced U251/brevican-shDNA 2 cells’ (b, d). TU, the transduced U251 cells; TU-shDNA mock, the transduced U251/brevican-mock cells;
TU-shDNA2, transduced U251/brevican-shDNA 2 cells; a, b, the plain MRT results; c, d, Gd-DTPA-enhanced MRT results. * P<0.05; ** P < 0.01.
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transduced U251 cells using loss-of function techniques.
We found that brevican knockdown affected cell inva-
sion and might explain how endogenous brevican exerts
its effects on cell adhesion. We confirmed that brevican
can promote glioma cell adhesion [15,25]. Moreover, a
distinct inhibition of the spreading and expression of
brevican was observed surrounding the core of sup-
pressed transduced U251 cells using a cytoimmunofluor-
escence assay. At this point we speculate that
mechanisms that recycle adhesion receptors via endoso-
mal compartments may contribute to migration. Results
from our wound-healing experiments confirm this
hypothesis.
Gliomas are highly invasive [26]. The ability of tumor
cells to interact with the components of the NECM
affects numerous cellular processes, and inappropriate
expression of these matrix components has been asso-
ciated with glioma invasion and growth [8,14]. One
NECM component that has been implicated in glioma
biology is brevican, and increasing studies have focused
on brevican and mechanisms of glioma invasion in re-
cent years [27]. Brevican’s involvement in glioma inva-
sion may explain why many physiological processes
require closely regulated degradation of the NECM [28].
In light of the effects of brevican on cell motility, we
investigated the tumorigenicity of differential brevican
expression in vivo. To date, little is known of the mo-
lecular basis that allows glioma cells to overcome the
barriers that inhibit motility in the adult nervous tissue
[29-31]. In this study, we found that brevican was highly
overexpressed in glioma and distinctively promoted cell
adhesion ability. The change of the NECM in the ner-
vous system is critical for tumor cell aggression and in-
vasion. To overcome the barriers to cell motility, glioma
cells degrade the NECM and secrete their own matrix
components. Our work demonstrated that the xenograft
transplants using brevican knockdown cells gave rise to
much smaller tumors, and had less diffuse and less infil-
trative tumors than those of control groups. Overall, the
deposition of brevican into the NECM may disrupt
matrix processing and alter extracellular molecular
events that modulate neural solubility.
Conclusions
This study indicates that the expression of brevican is
associated with glioma cell adhesion, motility and tumor
growth. Brevican also plays an important role in glioma
progression, and therefore, may be a useful marker
of glioma.
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